2203 completed, 213 terminated, 188 recruiting, 142 active not recruiting. 969 Phase 1, 829 Phase 2, 711 Phase 3, 286 Phase 4, 83 Not applicable.
Follow Eli Lilly and Company: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Tirzepatide, Placebo - Obesity | Phase 3 | Not yet recruiting | Universidade do Porto | 70 | 2027-01-01 | 2026-09-18 |
| A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Vepugratinib - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 161 | 2026-12-01 | 2026-10-08 |
| A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 192 | 2026-12-01 | 2026-10-13 |
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 50 | 2026-12-01 | 2026-08-24 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes eloralintide and tirzepatide, Eloralintide, Tirzepatide - Obesity | Phase 3 | Not yet recruiting | Eli Lilly and Company | 2115 | 2026-12-01 | 2026-10-19 |
| AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis | Phase 4 | Not yet recruiting | Forefront Dermatology S.C | 250 | 2026-11-11 | 2026-10-02 |
| A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease Donanemab - Alzheimer Disease | Phase 4 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-11-01 | 2026-10-15 |
| PET/CT Imaging of GRPR Expression in Various Tumors GRPR PET/CT - Malignancies Multiple | Early Phase 1 | Not yet recruiting | Jewish General Hospital | 60 | 2026-11-01 | 2026-09-18 |
| Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) Pirtobrutinib, Mosunetuzumab - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | University of Utah | 25 | 2026-11-01 | 2026-09-24 |
| A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes eloralintide and tirzepatide, Tirzepatide - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 1000 | 2026-11-01 | 2026-10-19 |
| A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). LY3873862, CYP450 Drug Cocktail, Placebo - Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System | Phase 1 | Not yet recruiting | Eli Lilly and Company | 32 | 2026-11-01 | 2026-10-20 |
| A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes Macupatide, Eloralintide, Placebo - Obesity, Overweight | Phase 1 | Not yet recruiting | Eli Lilly and Company | 60 | 2026-10-01 | 2026-08-14 |
| Baricitinib Curative Repression of HIV-1 Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV | Phase 2 | Not yet recruiting | Emory University | 35 | 2026-10-01 | 2026-08-17 |
| A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) LY4560736, Placebo, Florbetapir F18 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Not yet recruiting | Eli Lilly and Company | 111 | 2026-10-01 | 2026-10-08 |
| A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India Selpercatinib - Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 4 | Not yet recruiting | Eli Lilly and Company | 30 | 2026-10-01 | 2026-10-08 |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer Fam-Trastuzumab Deruxtecan-Nxki - Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 27 | 2026-10-01 | 2026-10-01 |
| A Study of LY4515100 in Healthy Male Participants [¹⁴C]-LY4515100 Oral Solution, LY4515100 Tablet, [¹⁴C]-LY4515100 IV - Healthy | Phase 1 | Not yet recruiting | Eli Lilly and Company | 16 | 2026-10-01 | 2026-10-09 |
Showing 20 of 2890. Sign in to see all of them.
Diabetes Mellitus, Type 2 (380) · Carcinoma, Non-Small-Cell Lung (190) · Obesity (132) · Breast Neoplasms (121) · Diabetes Mellitus (117) · Overweight (94) · Diabetes Mellitus, Type 1 (91) · Neoplasm Metastasis (88) · Neoplasms (88) · Depressive Disorder, Major (74) · Alzheimer Disease (71) · Attention Deficit Disorder with Hyperactivity (67) · Lung Neoplasms (54) · Schizophrenia (54) · Colorectal Neoplasms (49)
Pemetrexed (172) · Gemcitabine (171) · Duloxetine Hydrochloride (127) · abemaciclib (120) · Cisplatin (105) · Tirzepatide (92) · Carboplatin (90) · Insulin Lispro (89) · Insulin Glargine (85) · Ramucirumab (84) · Cetuximab (76) · baricitinib (72) · Atomoxetine Hydrochloride (68) · Exenatide (62) · Olanzapine (60)
United States (1924) · Germany (542) · Spain (451) · Japan (440) · Canada (418) · France (380) · United Kingdom (361) · Italy (334) · Poland (313) · Mexico (302) · Puerto Rico (299) · Australia (280) · South Korea (272) · Belgium (261) · Argentina (240)
James Malone, MD (17)
PMID 25019647, PMID 35472672, PMID 22236356, PMID 34473343, PMID 38770818, PMID 22913891, PMID 36542287, PMID 25080392, PMID 33826132, PMID 34706874, PMID 34795131, PMID 29463520, PMID 31482569, PMID 35210595, PMID 24919854, PMID 26691396, PMID 27161178, PMID 32576229, PMID 35279805, PMID 35713300, PMID 36255569, PMID 36894938, PMID 40603145, PMID 20537128, PMID 20537130, PMID 21095016, PMID 21102344, PMID 23748506, PMID 24119319, PMID 24423017, PMID 24650448, PMID 27685842, PMID 30219772, PMID 31505082, PMID 31952501, PMID 32306296, PMID 37400681, PMID 37526908, PMID 37668888, PMID 39531161, PMID 39963952, PMID 22249355, PMID 22967772, PMID 25980552, PMID 26120369, PMID 26299520, PMID 26402769, PMID 27316632, PMID 28357715, PMID 28417532
2015 (52), 2025 (45), 2023 (42), 2019 (41), 2017 (38), 2016 (36), 2018 (30), 2009 (20), 2014 (18), 2008 (7), U01AG059798 (3), 2005 (2), R01AG046179 (2), U01AG042791 (2), U10CA031946 (2)